SEAL Therapeutics AG: Gene therapy for muscular dystrophy The Biozentrum spin-off develops an innovative gene therapy to treat congenital muscular dystrophy. Cross-section through treated LAMA2 MD muscle with individual…
LRBA deficiency is a rare and severe autoimmune disorder that was first described in 2012. This disease is caused by a genetic defect in the LRBA gene and is characterized by an impaired immune response and autoimmunity.…
CV of Prof. Dr. Knut Drescher ORCID 0000-0002-7340-2444 Google Scholar Google Scholar Positions: Since 2021 Associate Professor at the Biozentrum 2015 - 2021 Professor of Biophysics, Philipps-Universität Marburg 2014 - 2021…
FACS Core Facility Fluorescence Activated Cell Sorting (FACS) is a technology with which mixtures of cells can be analyzed, counted and separated with a special instrument, the flow cytometer. This procedure is already being…
Prof. Ben Engel on recognizing our connection with the environment Ben Engel about his childhood in California, his love of nature, and the importance of scientific communication. You grew up in California - how would you…
The goal of the ERC Advanced Grants is to support established, leading principal investigators to pursue a groundbreaking and high-risk project. As all ERC grants, they are in high demand and therefore very competitive. This…
The company NextImmune , founded at the Biozentrum of the University of Basel in 2021, focuses on the development of selective immunosuppressive therapy. This novel class of drugs specifically suppresses the immune system…
Interview with Seraphine Lüscher She practically adopted the protein assigned to her in the Experimental Molecular Biology course. Being able to conduct experiments from A to Z already in her second year of studies was a…
The European funded research project CANDY investigates the underlying mechanisms of co-morbidities in neurodevelopmental diseases. “By looking at the mechanisms underpinning neurodevelopmental disorders it is our aim to…
This website uses cookies to collect data from users and improve functionality. By continuing to browse the site you are agreeing to this. Receive more information by reading our privacy policy.
